THERAPY DOSSIER · th-7a7247d425fb

Lipoxin A4 (LXA4); BOC-2 used as a receptor antagonist in a mechanistic reversal arm

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02626169 ↗PHASE4withdrawn

The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation

Atherosclerosis

Enrolment: 0 · Results not recorded

NCT01040819 ↗PHASE4completed

Does Pioglitazone Increase the Production of Prostacyclin (PGI2) and/or 15-EPI-Lipoxin A4 in Humans With Diabetes Mellitus Type 2?

Type 2 Diabetes Mellitus

Enrolment: 25 · Results not recorded

NCT02342691 ↗PHASE1/PHASE2completed

A Phase 1 / 2 Clinical Trial to Assess the Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

Gingival Inflammation

Enrolment: 127 · Results not recorded

NCT06700161 ↗Phase not recordedcompleted

Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Gingival Crevicular Fluid in Individuals With Stage 3 Grade A Periodontitis

Peridontal Disease

Enrolment: 60 · Results not recorded

NCT03609541 ↗Phase not recordedunknown

Evaluation of Biomarkers of COPD Exacerbation

SAA Level and SAA/Lipoxin A4 Ratio

Enrolment: 80 · Results not recorded

NCT05417061 ↗NAcompleted

Serum and Saliva Sirtuin 6, Lipoxin A4, Caspase8 Levels in Correlation With Periodontal Status in Severe Periodontitis

Periodontitis · Diagnose Disease

Enrolment: 40 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31152979 ↗2019Reported benefit

Lipoxin A4 reduces hyperoxia-induced lung injury in neonatal rats through PINK1 signaling pathway

RatOtherSprague-Dawley (from PubMed MeSH indexing; not stated in the abstract)

Model: Hyperoxia-induced neonatal lung injury modelling bronchopulmonary dysplasia, produced by exposure to 85% oxygen for 7 days from birth

Lipoxin A4 significantly reduced cell and protein infiltration and oxidative stress in the lungs of hyperoxia-exposed neonatal rats, improved pulmonary function and alveolar simplification, and promoted weight gain. It inhibited TNF-alpha, MCP-1 and IL-1beta in serum and bronchoalveolar lavage flui…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…